<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136761">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320943</url>
  </required_header>
  <id_info>
    <org_study_id>GS-EU-174-0160</org_study_id>
    <secondary_id>2010-021925-12</secondary_id>
    <nct_id>NCT01320943</nct_id>
  </id_info>
  <brief_title>Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB</brief_title>
  <acronym>FINITE CHB</acronym>
  <official_title>FINITE CHB - First Investigation in Stopping Tenofovir Disoproxil Fumarate (TDF) Treatment After Long Term Virologic Suppression in HBeAg-negative Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Withdrawal of antiviral therapy can result in hepatic or alanine aminotransferase (ALT)
      flares as Hepatitis B Virus (HBV) replication resumes; however, in some participants, a
      flare exacerbates chronic hepatitis temporarily but can also result in viral clearance.
      Hepatic flares are common after stopping anti-HBV therapy.

      Only participants who already are on treatment with tenofovir disoproxil fumarate (TDF)
      monotherapy or TDF in combination with lamivudine or emtricitabine for at least 4 years and
      who achieved and maintained virologic suppression (&lt; 400 copies/mL) for 3.5 or more years
      will be included in this study. One treatment arm will stop the TDF therapy while the other
      treatment arm will continue the TDF therapy.

      Participants in the Stop TDF arm will be monitored very closely with special focus on
      biochemical flares (especially ALT increases) and virological relapses (Hepatitis B viral
      load increases). If any participant in the Stop TDF arm exceeds one or more predefined
      limits for such flares or relapses, TDF will be reinstituted.

      The study will assess Hepatitis B surface antigen (HBsAg) loss (i.e. specific Hepatitis B
      virus components are no longer detectable) and seroconversion (occurrence of Hepatitis B
      surface antibody, a specific antibody which usually occurs after HBsAg loss) rates during
      study duration. The percentage of participants who need to restart TDF therapy in the Stop
      TDF arm will also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with HBsAg loss at Week 144 in both study arms</measure>
    <time_frame>Week 144</time_frame>
    <description>The proportion of participants with HBsAg loss will be evaluated using the Kaplan-Meier (KM) product limit method. Participants who have not experienced HBsAg loss but discontinue from the study prior to Week 144 are considered censored at the last HBsAg collection date. Log-rank test statistic will be used to compare the time to HBsAg loss between the two treatment arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with seroconversion in both study arms</measure>
    <time_frame>Weeks 96 and 144</time_frame>
    <description>The proportion of participants with seroconversion at Weeks 96 and 144 and will be summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quantitative HBsAg (IU/mL) in both study arms</measure>
    <time_frame>Baseline to Week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who restart TDF therapy in the Stop TDF arm</measure>
    <time_frame>Weeks 48, 96, and 144</time_frame>
    <description>The proportion of participants who restart TDF therapy in Stop TDF arm at Weeks 48, 96 and 144 will be estimated using the Kaplan-Meier (KM) product limit method. Participants who have not re-started TDF therapy but discontinue from the study will be considered as censored at the last laboratory collection date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with viral suppression in the Stop TDF arm</measure>
    <time_frame>Baseline to Week 144</time_frame>
    <description>Viral suppression is defined as not having two consecutive HBV DNA ≥ 400 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ALT &lt; upper limit of the normal range in the Stop TDF arm</measure>
    <time_frame>Baseline to Week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with HBsAg loss at Week 96 in both study arms</measure>
    <time_frame>Week 96</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Stop TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm will stop TDF therapy at baseline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continue TDF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to this arm will continue TDF therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF</intervention_name>
    <description>Tenofovir disoproxil fumarate (TDF) 300 mg tablet administered orally once daily</description>
    <arm_group_label>Continue TDF</arm_group_label>
    <other_name>Viread®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stop TDF</intervention_name>
    <description>Participants will stop TDF therapy</description>
    <arm_group_label>Stop TDF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis B, hepatitis B e-antigen negative, hepatitis B e-antibody positive,
             and hepatitis B surface antigen-positive

          -  Hepatitis B e Antigen (HBeAg)-negative at the beginning of TDF therapy (i.e. TDF
             monotherapy or combination of TDF + lamivudine or TDF + emtricitabine)

          -  Received continuous TDF therapy (i.e. TDF monotherapy or combination of TDF +
             lamivudine or TDF + emtricitabine) treatment for at least 4 years prior to screening.
             If TDF has been used in combination with lamivudine or emtricitabine, lamivudine or
             emtricitabine must have been stopped at least 12 weeks prior to screening

          -  Documented hepatitis B virus DNA (HBV DNA) &lt; 400 copies/mL for at least 3.5 years
             prior to screening and at screening

          -  ALT within normal range

          -  α-fetoprotein (AFP) &lt;= 50 ng/mL

          -  Calculated creatinine clearance &gt;= 70 mL/min by Cockcroft-Gault formula using ideal
             body weight

          -  &lt;= 10 kPa on Fibroscan assessment

          -  A negative serum pregnancy test for female subjects

          -  Adult subjects &gt;= 18 years of age

        Exclusion Criteria:

          -  Known cirrhosis

          -  Evidence of fibrosis &gt;= Stage 3 (METAVIR) on liver biopsy or Fibroscan &gt; 10 kPa
             within 6 months prior to screening

          -  Documentation of confirmed episodes (i.e., 2 consecutive values) of HBV DNA &gt; 400
             copies/mL within 3.5 years prior to screening

          -  History of decompensated liver disease (defined as direct [conjugated] bilirubin &gt;
             1.5 x upper limit of normal, prothrombin time (PT) &gt; 1.5 x upper limit of normal,
             platelets &lt; 75,000/mm³, serum albumin &lt; 3.0 g/dL

          -  History of clinical hepatic decompensation in the judgement of the investigator

          -  Evidence of hepatocellular carcinoma

          -  Significant bone disease (in the judgment of the investigator)

          -  Serological evidence of coinfection with human immunodeficiency virus (HIV),
             hepatitis C virus, or hepatitis D infection

          -  Known hypersensitivity to TDF, its metabolites, or formulation excipients

          -  Concomitant therapy with disallowed medications

          -  History of malignant disease

          -  Lactating females

          -  Females wishing to became pregnant during the duration of the stud

          -  Subjects participating in another clinical trial can only be enrolled at the
             discretion of the Medical Monitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marjoleine L Op den Brouw</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leberzentrum am Checkpoint</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite CVK</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für HIV und Hepatitis</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40237</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J.W. Goethe Universitaetsklinikum</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ifi Studien und Projekte GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologische Gemeinschaftspraxis</name>
      <address>
        <city>Herne</city>
        <zip>44623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Gastroenterologie</name>
      <address>
        <city>Leverkusen</city>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der LMU Grosshadern</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 29, 2016</lastchanged_date>
  <firstreceived_date>March 9, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stopping oral antiviral therapy</keyword>
  <keyword>HBsAg loss</keyword>
  <keyword>seroconversion</keyword>
  <keyword>restarting oral antiviral therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Tin Fluorides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
